Intercept strikes market sweet spot with $75m IPO
This article was originally published in Scrip
Intercept Pharmaceuticals seems to have found the mood of the stock market with its $75 million initial public offering of 5 million shares priced at $15 per share on 11 October. Unlike many recent IPOs, New York-based Intercept did not have to reduce the size or price of its offering in order to encourage investors to buy in.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.